AU2005237364B2 - Method for reducing gastrointestinal toxicity due to the administration of tegafur - Google Patents

Method for reducing gastrointestinal toxicity due to the administration of tegafur Download PDF

Info

Publication number
AU2005237364B2
AU2005237364B2 AU2005237364A AU2005237364A AU2005237364B2 AU 2005237364 B2 AU2005237364 B2 AU 2005237364B2 AU 2005237364 A AU2005237364 A AU 2005237364A AU 2005237364 A AU2005237364 A AU 2005237364A AU 2005237364 B2 AU2005237364 B2 AU 2005237364B2
Authority
AU
Australia
Prior art keywords
tegafur
administration
patient
medicament
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005237364A
Other languages
English (en)
Other versions
AU2005237364A1 (en
Inventor
Hiroshi Ambe
Jun Kuritani
Naruo Nomura
Takeshi Tahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2005237364A1 publication Critical patent/AU2005237364A1/en
Application granted granted Critical
Publication of AU2005237364B2 publication Critical patent/AU2005237364B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005237364A 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur Ceased AU2005237364B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US60/566,180 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (2)

Publication Number Publication Date
AU2005237364A1 AU2005237364A1 (en) 2005-11-10
AU2005237364B2 true AU2005237364B2 (en) 2010-07-08

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005237364A Ceased AU2005237364B2 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Country Status (16)

Country Link
US (1) US20080166427A1 (https=)
EP (1) EP1750703B1 (https=)
JP (1) JP5376758B2 (https=)
AT (1) ATE540679T1 (https=)
AU (1) AU2005237364B2 (https=)
CY (2) CY1112451T1 (https=)
DK (1) DK1750703T3 (https=)
ES (1) ES2378072T3 (https=)
HR (1) HRP20120293T1 (https=)
ME (1) ME01335B (https=)
PL (1) PL1750703T3 (https=)
PT (1) PT1750703E (https=)
RS (1) RS52217B (https=)
RU (1) RU2348409C2 (https=)
SI (1) SI1750703T1 (https=)
WO (1) WO2005105086A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
CN102648412A (zh) * 2009-07-17 2012-08-22 美瑞德生物工程公司 5-fu的检测方法
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944088C (en) * 2014-03-28 2022-06-21 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
EP3290038A4 (en) * 2015-04-30 2018-12-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating adverse reaction to antitumor drug
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
US20250186435A1 (en) * 2020-05-19 2025-06-12 Cellix Bio Private Limited Pharmaceutical formulations and their preparations for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NL194430C (nl) * 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543015A1 (en) * 1991-05-27 1993-05-26 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOLLET P et al. European Journal of Cancer. 2003. 39(9): 1264-1270 *
DAMLE B et al. Clinical Cancer Research. 2001. 7(3): 517-523 *
PETERS GJ et al. Cancer Chemotherapy and Pharmacology. 2003. 52(1): 1-12 *
SAKATA Y et al. European Journal of Cancer. 1998. 34(11): 1715-1720 *

Also Published As

Publication number Publication date
ATE540679T1 (de) 2012-01-15
DK1750703T3 (da) 2012-05-07
RS52217B (sr) 2012-10-31
ME01335B (me) 2013-12-20
SI1750703T1 (sl) 2012-02-29
AU2005237364A1 (en) 2005-11-10
EP1750703B1 (en) 2012-01-11
CY2012014I1 (el) 2016-04-13
US20080166427A1 (en) 2008-07-10
RU2348409C2 (ru) 2009-03-10
CY1112451T1 (el) 2015-12-09
EP1750703A1 (en) 2007-02-14
PL1750703T3 (pl) 2012-05-31
HRP20120293T1 (hr) 2012-04-30
WO2005105086A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
JP5376758B2 (ja) 2013-12-25
ES2378072T3 (es) 2012-04-04
PT1750703E (pt) 2012-02-23
CY2012014I2 (el) 2016-04-13
EP1750703A4 (en) 2008-02-27
RU2006142101A (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
AU2005237364B2 (en) Method for reducing gastrointestinal toxicity due to the administration of tegafur
EP1849470B2 (en) Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
AU2009268469B2 (en) Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway
US20110190312A1 (en) Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof
WO2022109307A1 (en) Treatment of kras mutant cancers
US20180338976A1 (en) Method for treating cancer patients with severe renal impairment
WO2024238628A1 (en) Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein arginine methyltransferase 5 (prmt5) inhibitor
US20050267140A1 (en) Method for treating abnormal cell growth
TW202045155A (zh) 用於治療癌症之組合療法
CZ300791B6 (cs) Lécivo pro lécení nádoru nadexprimujících GSH/GSTs systém
AU2006231808B2 (en) Radiotherapy enhancer
Scheulen et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
EP2298309B1 (en) Antitumor agent, kit and method of treating cancer
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
AU2022343745B2 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors
KR20260059496A (ko) Sos1 저해제 및 kras 저해제를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
HK40103356A (zh) Kras突变型癌症的治疗
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan
HK40046131B (en) Quinoline derivative used for treating small cell lung cancer
HK1261379B (en) Deuterated compounds for treating cancer and compositions and methods thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired